One of the most exciting projects in which CRS is now engaging is POLYMORPH, a new generation of automation technologies. Included in Polymorph is a new release of POLARA (CRS' proprietary process control and scheduling software), as well as novel mechanical/electrical dimensions. It promises to allow high degrees of modularity and increased speed in the automated laboratory's search for new drugs targeted to specific disease sites. POLYMORPH is expected to offer a significant increase in scalability, system flexibility and assay throughput. In recent years the advent of combinatorial chemistry and genomics has exponentially expanded the available number of compound/disease targets confronting the screening laboratory in the search for new drugs. This results in the need to test millions of compound combinations. POLYMORPH will be designed to accept newer nanotitier assay plates, complementing recent trends in miniaturization intended to increase compound screening throughput and reduce per unit test costs. Chief Technical Officer Trevor Jones said of the nanotech field, "We have to be leading the technology wave." He also said that from POLYMORPH would come even greater flexibility, allowing companies to buy today only what they need today.
POLYMORPH will fully embrace the POLARA Open Architecture Software System designed by CRS. POLARA, backbone software architecture used exclusively in high-speed lab automation, is entering its third rendition following its acceptance in scores of research labs worldwide. POLYMORPH hardware and POLARA software will be mutually complementary in increasing laboratory productivity.
In other areas CRS has recognized the recent trend for laboratories to engage in their own automation integration. This next generation laboratory buys the "building blocks" from CRS, whether it is POLARA, a peripheral device or a robot, CRS feels that modularity is what differentiates CRS from the competition. Companies can buy the full package, or just the software to integrate with another company's instruments. Therefore, CRS is going more "mainstream" on software languages. They have their own proprietary language, RAPL 3, but are also moving POLARA over to COM based languages such as Visual Basic, and Visual C++, making it an open and accessible standardization that is easier to learn. They expect that standardization will drive the life science industry in the near future.
Standardization provides the way for introducing flexibility and modularity to the HTS laboratory. Most systems remain dedicated to a particular type of instrumentation. It is difficult, therefore, to change any aspect of the process. CRS believes one of their strengths to be the practice of listening to company needs, building reliable and competitively priced solutions to meet these needs, and building them in a modular fashion to extend flexibility. CRS looks at applications, consults, and builds the best solution with considerable customer input. CRS is able to use the modular approach because it employs standardized instrument interfaces and internally engineered peripherals designed for lab automation.
CRS also intends to increase its capabilities in biology and chemistry as many of their competitors have. This will enable CRS to develop assays, or consumables in conjunction with automation that complements assay demands.
On the software front, CRS has just announced the availability of ActiveRobot™, a new software tool for CRS robotics systems. The new software is the first of its kind from CRS and promises simplified programming without the need for proprietary lan-guages. CRS foresees that the new software will appeal to anyone with compatible CRS equipment as well as system integrators with a need to automate workstations and small systems. A special web site (www.activerobot.com) has been set up for technical support and downloading.
MISSION
CRS views its role as being the leading provider of solutions that best meet the productivity needs of their customers without imposing an instrument bias. The new tagline, It's all about time, means that robots, though important, are a peripheral part of a laboratory automation company seeking to partner itself with laboratory customers facing huge time challenges. CRS has a number of philosophical themes to add meaning to the slogan: The utility of Laboratory integration software (POLARA) and the durability of the mover (robot) are only two of them.
It's all about time also refers to the notion of shortening the time in which CRS produces products and gets them to market, focusing on customer needs, understanding the market and what is required. To this end they have instigated a "Stage Gate Process" for all new products. This is heavily weighted toward meeting customer needs for affordable, reconfigurable and reliable automation solutions that are focused on customer assay expectations.
In the CRS definition of Life Sciences: Pharmaceutical and Biotech markets are the broad vertical markets in which the company seeks customers that value suppliers with a partner focus. Drug discovery is an important segment. The company initially developed an expertise in the high throughput screening market, however CRS is equipped to provide solutions for the entire drug development chain including the automation of clinical trial assays.
HUMAN GENOM E PROJECT
CRS branched from HTS into the Human Genome Project to satisfy customer demands. The human genome market is anticipated to grow enormously as scientists begin to find practical applications of the human genome map. CRS has, in fact, already provided automation solutions to the Joint Genome Institute, the Institute for Genomic Research (TIGR), Integrated Genomics and the Australian Genome Project, to name but a few.
As early as 1992, CRS was working on a robotic project for the Whitehead Institute. By 1997, the Whitehead Institute had purchased five more systems from CRS including POLARA software to control the fully automated systems. Trevor Hawkins (Deputy Director, United States Department of Energy Joint Genome Institute) was with the Whitehead Institute at that time. He was impressed as early as 1992 with CRS' flexibility. In his present position he has continued to work with CRS. So far, the Joint Genome Institute has purchased three CRS DNA purification systems, and two sequencing chemistry systems. Hawkins described CRS as "extremely knowledgeable in laboratory automation," and thorough at, "adapting systems to meet our lab needs." Dr. Hawkins also stressed the value he puts on the service CRS provides after shipment, saying, "Their support has been truly excellent."
Hansjoerg Haas, Ph.D., (Managing Director of Laboratory Automation), joined the company in early 1997. He believed then that the company needed to focus on laboratory automation. Haas and his colleagues soon realized that they were strong in HTS, but also realized genomics would play a large role in future pharmaceutical HTS. CRS now has made its mark with two genomic systems in Australia, systems in Sweden, closed orders with the Joint Genome Institute. CRS has now made its mark on the international genomic stage with two genomic systems in Australia and systems in Sweden. Added to this are closed orders for genomic systems with Monsanto and Canada's National Research Council
The future breakthroughs in the genomic field are expected to come from three areas structural, functional and pharmacogenomics all hold promise and laboratory automation challenges. In the first stage: The Human Genome Project will provide the all-important sequencing data of human DNA, contained in the 100,000 individual genes and the base pair combinations estimated to number 3 billion. But this, in itself, does not reveal all the answers. In the second stage, Functional Genomics address the questions: What do these genes do? What are the functions? CRS is designing and delivering systems to deal with this. The final stage, Pharmacogenomics, will be aimed at using the new knowledge to screen specific drug candidates targeted to interact with gene proteins responsible for specific disease processes. In such a scenario, CRS anticipates that throughput demands will be very high as genomics, combined with existing and new combinatorial libraries, dramatically and exponentially expand compound/target combinations. Fast, reliable and flexible systems will be needed. Bioinformatics, alone, will be daunting and this has prompted CRS to address this in both its new systems and software.
Traditional Pharmaceutical HTS is becoming a mature market in which customers have specific demands. In contrast, the applied genomics market is still in search of ideal technological solutions to address these new analytical challenges.
Haas also believes that dedication to quality has paid off for CRS. The company is ISO 9001 registered and has engineers, scientists and software developers bringing their combined strengths to a revamped, customer focused organization. Haas is proud to relay the fact that CRS has been subjected to three consecutive external quality audits without a single serious deficiency. Looking ahead, CRS now have hardware and motion control software and are building up more in application knowledge that will have a broad range of applications in genomics as well as drug discovery. Even in robotics, the company is not standing still. Technical improvements in robot models, including a new 3-axis robot specifically for lab applications, are also in the works.
In the meantime, CRS supplies HTS and Ultra HTS systems designed for drug screening as well as complete genomic solutions. At LabAutomation 2000, the CRS Ultra HTS system on display produced a throughput of 184,000 data points a day using stacker technology that totally eliminated the robot as the ratelimiter in data output. CRS claims that this system also offers a superior cost/output ratio.
The National Research Council of Canada recently purchased a hybrid DNA purification/amplification system from CRS. The implementation was completed two months ago. Dr. William Crosby (Program Leader, Plant Genomics, at the National Research Council's Plant Biotechnology Institute in Saskatoon, Canada) explained that they looked in detail at the options for automating their work in agrogenomics. After having researched a variety of options, Crosby felt that, "CRS offered the flexibility, and the ability to integrate third party equipment with the robotic arm". The fact that CRS was a Canadian company was considered an added bonus, but was not the main reason for selecting them. Overall Dr. Crosby said that he was, "very happy with the performance of the system".
CRS prides itself in being an industry leader in providing open architecture software tool kits to their customers. "Providing open architecture systems and source code to robot users will stimulate widespread utilization of robotics in laboratories," stresses Robin A. Felder, President and CEO of the Association for Laboratory Automation.
CRS also offers training in systems administration, operation, advanced programming, computer server configuration, and robotic servicing. CRS claims that a customer can be as dependant on or independent of CRS as their situation calls for. The choice is entirely customer-driven. Training for Laboratory Automation includes putting the robot system through simulated procedures based on real assay demands. When the product is ready for delivery, CRS system specialists take it apart, ship it to the customer's site where it is reassembled and re-tested from scratch. The customer usually requires training in the CRS center for only a few days to complete the process.
CRS SALES
In 1999, 60% of CRS sales were in the US (up from 40% in 1998,) 30% into Europe, with the remaining 10% scattered around the world. CRS has customized solutions and standardized hardware to address the needs of the 1300 biotech companies in Europe as well as the 1500 in the US. Canada also represents an important market for CRS. The Canadian government and some provincial government, are in fact starting to provide funding in the genome area. Genome Canada was established in 1999, funded by the Canadian Federal Government. CRS expects to get much of this business given its already developed knowledge base in high throughput genomics, software, application know-how and custom lab automation integration experience.
THE HISTORY OF CRS
CRS Robotics Inc., began in 1981 with four people in the engineering faculty of a local university with an idea. The idea was human scale robotics. Their first robot was capable of lifting one kilogram and was used in a hospital laboratory. They continued to focus on this type of robot throughout the 1980' s, when they attracted venture capital funding. In the mid 1990's CRS decided to go public. They had requests for robots for many applications including uses in laboratory quality control automation.
In 1996, CRS purchased a German company with expertise in machine, vision and laboratory automation. The German expansion was characterized by an aggressive research and development program that resulted in the F3 Robot, a 3 kilogram robot with novel communication and control architecture. The integration software (POLARA) needed to support their entry to the laboratory automation business, was brought to market in July 1998.
Coterminous with that process was a decline in the German operation and an increase in R&D costs. The combined effect was to put CRS into a loss situation. 1997 was a key year. The company cut back, restructuring its Board of Directors. By early 1998, CRS had withdrawn from Germany and appointed Ralph Steedman as President and CEO. He had previously been Executive Vice President of Locator Group Inc. Steedman holds an MBA from Toronto's York University. In 1999, CRS started to add people and expand its biotechnology focus. The plan for 2000 was simple; it was the breakout year for the company. Revenue for the first quarter is up 30%. This was the 9 th consecutive quarter of CRS profitability.
STRATE GIC RE-DIRECTION AND THE FUTURE
CRS is trying to further enhance its image as a biotechnology company. 74% of sales in 1999 were in the life sciences. "We are a life science company," says Steedman. The continued focus at CRS will be on automation solutions targeted to the life sciences including pharmaceutical, biotechnology, institutional research and drug discovery endeavors.
In summary, CRS intends to be a leading automation provider by fulfilling customer needs. They expect to grow by at least 30% per year by direct sales and company acquisitions. They will further expand by introducing new product lines, such as bio-informatics. Expansion shall also be achieved through collaboration with existing companies, funding start-up companies, and partnering with key academic institutions. The emerging clinical laboratory and medical automation markets presents an exciting challenge for CRS. CRS' core competencies are motion control, software, system design and building custom integrated systems. They believe that customers are not just buying a system but a solution. For this reason, CRS has developed a capability in designing and building peripheral devices specifically for lab automation and re-engineering instruments to enhance automation friendliness and system compatibility. The requirements of the assay drive system design.
Trevor Jones (Chief Technical Officer) describes CRS' role as "Creating productivity for our customers." In the future he perceives the hunger for diverse products driving the automation market. In life sciences, flexibility and reliability are paramount. Equally important is implementing all industry standards. What CRS intends to offer is not harder automation, but "smarter automation."
A conversation with Jones also supports Ralph Steedman's opinion that CRS has used all of its know-how in engineering, software development and application automation to develop a customer focused company well beyond its humble origins. Even CRS customers seem to agree that the company, once renowned for the reliability of its venerable robots, has decidedly become much more than just that. n The CRS Ultra HTS System
